Furthermore, we found that patients with high DEPDC5 expression survived longer than those with low DEPDC5 expression across different tumor types in The Cancer Genome Atlas (TCGA) cohorts, including pheochromocytoma and paraganglioma (PCPG), colonic adenocarcinoma (COAD), lung adenocarcinoma (LUAD), bladder urothelial carcinoma (BLCA) (Fig. 1d). This evidence concerns the gene DEPDC5 and neoplasm.